Who are Axitinib (AG-013736)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Inlyta, Sunitinib (Sutent), Letybo®, Sequential and maintenance icotinib, Erlotinib, Pemetrexed, lorlatinib plus chemotherapy.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/axitinib-ag-013736.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Axitinib (AG-013736) — Competitive Intelligence Brief

Axitinib (AG-013736) (axitinib-ag-013736) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: tyrosine kinase inhibitor. Area: Oncology.

marketed tyrosine kinase inhibitor vascular endothelial growth factor receptors (VEGFRs) Oncology Live · refreshed every 30 min

Target snapshot

Axitinib (AG-013736) (axitinib-ag-013736) — Pfizer.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Axitinib (AG-013736) TARGET	axitinib-ag-013736	Pfizer	marketed	tyrosine kinase inhibitor	vascular endothelial growth factor receptors (VEGFRs)
Inlyta	Axitinib	Pfizer	marketed	Receptor tyrosine kinase inhibitor	Vascular endothelial growth factor receptors (VEGFR)-1, VEGFR-2, VEGFR-3	2012-01-01
Sunitinib (Sutent)	Sunitinib (Sutent)	Sponsor GmbH	marketed	Multi-targeted tyrosine kinase inhibitor	VEGFR, PDGFR, KIT, FLT3
Letybo®	Letybo®	Yuvell	marketed	FLT3 inhibitor / multi-targeted tyrosine kinase inhibitor	FLT3, JAK2
Sequential and maintenance icotinib	Sequential and maintenance icotinib	Betta Pharmaceuticals Co., Ltd.	marketed	EGFR tyrosine kinase inhibitor	EGFR
Erlotinib, Pemetrexed	Erlotinib, Pemetrexed	Hunan Province Tumor Hospital	marketed	EGFR tyrosine kinase inhibitor + antifolate antimetabolite	EGFR; thymidylate synthase and folate-dependent enzymes
lorlatinib plus chemotherapy	lorlatinib plus chemotherapy	The First Affiliated Hospital of Guangzhou Medical University	marketed	ALK tyrosine kinase inhibitor (combination therapy)	ALK (anaplastic lymphoma kinase), ROS1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (tyrosine kinase inhibitor class)

Centre Leon Berard · 2 drugs in this class
Akeso · 1 drug in this class
Astex Pharmaceuticals, Inc. · 1 drug in this class
Chengdu Zenitar Biomedical Technology Co., Ltd · 1 drug in this class
Jiangsu HengRui Medicine Co., Ltd. · 1 drug in this class
Jiangsu ShengDiYa Medicine Co., Ltd. · 1 drug in this class
Nanjing Leads Biolabs Co.,Ltd · 1 drug in this class
Ocular Therapeutix, Inc. · 1 drug in this class
Peking University Cancer Hospital & Institute · 1 drug in this class
Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Axitinib (AG-013736) — Competitive Intelligence Brief. https://druglandscape.com/ci/axitinib-ag-013736. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab